FDA Calendar

Biotech Catalyst and FDA Calendar for your biotech investing. FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates. 

The catalyst date is the LATEST expected date for the catalyst to occur by.  For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the “FDA Calendar Glossary” for a list of terms used in the FDA Decision Calendar.

AMEX and NASDAQ companies are listed. Generally no OTC/PINK companies are listed unless the upcoming catalyst is a PDUFA or Advisory Committee event. LARGE cap companies are generally NOT featured in the database unless it is a PDUFA or Advisory Committee event.

Pipeline data are current and updated daily

Financial data are updated at the end of each trading day.

Showing 404 drugs
Ticker Price Drug Stage Catalyst
ARRY
$3.38
-0.08  (-2.03%)
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 2
Phase 2 data to be presented at the European Society of Cardiology on August 30, 2016
RIGL
$2.88
+0.07  (+2.49%)
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
Phase 3
Phase 3 data from the first trial due August 2016 with data from the second trial due October 2016
XOMA
$0.60
+0  (+0.31%)
XOMA 358
Hypoglycemia Post Gastric Bypass Surgery
Phase 2
Phase 2 initiated April 2016. Update expected summer 2016
BLRX
$0.86
-0.02  (-2.15%)
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory
Phase 2
Phase 2 data released March 2016. Full set of data to be presented September 7-10, 2016
CLCD
$8.50
-0.21  (-2.41%)
Lasmiditan - SAMURAI
Migraine
Phase 3
Phase 3 enrolling. Top-line data available week of September 5.September 9 listed as last possible date.
ARLZ
$5.45
-0.08  (-1.45%)
YOSPRALA (PA32540/PA8140)
Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers
PDUFA
PDUFA date September 14 2016
ACHN
$9.22
-0.08  (-0.75%)
Odalasvir (ACH-3102), simeprevir and ALS-335
Hepatitis C (HCV)
Phase 2a
Phase 2a top-line data due September 23 2016 at EASL
ALNY
$75.79
-0.39  (-0.51%)
ALN-GO1
Primary Hyperoxaluria Type 1 (PH1)
Phase 1/2
Phase 1/2 initiated March 2016. Initial data September 24 2016
DRRX
$1.85
-0.01  (-0.54%)
Remoxy
Chronic pain
PDUFA
PDUFA September 25 2016.
PTIE
$2.40
-0.05  (-2.04%)
Remoxy
Chronic pain
PDUFA
PDUFA September 25 2016. Company advised that the FDA has determined that the Advisory Committee tentatively scheduled for August 5 2016 is NO LONGER REQUIRED
ABUS
$3.96
+0.02  (+0.51%)
ARB-1467
Hepatitis B (HBV)
Phase 2
Phase 2 single dose data due 3Q 2016, multiple dose data due 4Q 2016
ACRS
$21.24
+0.44  (+2.12%)
A-101
Common warts (verruca vulgaris)
Phase 2
Phase 2 data due 3Q 2016
ACRX
$3.50
+0.05  (+1.45%)
ARX-04 (SAP303)
moderate-to-severe acute pain following a surgical procedure
Phase 3
Phase 3 top-line data due 3Q 2016, with potential NDA filing by end of 2016
AERI
$19.73
+0.27  (+1.39%)
Roclatan - Mercury trials
Glaucoma
Phase 3
Phase 3 Mercury 1 data due September 2016. Mercury 2 trial data due 2Q 2017
AERI
$19.73
+0.27  (+1.39%)
Rhopressa
Glaucoma
NDA Filing
NDA filing due 3Q 2016
ALDR
$33.31
+0  (+0%)
ALD403
Chronic Migraine
Phase 2b
Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ARIA
$10.60
+0.04  (+0.38%)
Brigatinib - ALTA trial
Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC)
NDA Filing
NDA rolling submission filed June 2016. Submission to be completed 3Q 2016
ARRY
$3.38
-0.08  (-2.03%)
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 3
Phase 3 data due 3Q 2016
ATRS
$1.30
+0.14  (+12.07%)
VIBEX QuickShot
Testosterone deficiency
NDA Filing
Phase 3 data are due 3Q 2016. NDA to be filed late 2016.
CTIC
$0.35
-0.01  (-1.21%)
Pacritinib
Myelofibrosis
Phase 3
PERSIST-2 data due 3Q 2016. Currently on clinical hold
CYTX
$2.19
+0  (+0%)
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Phase 2
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
DPRX
$11.23
-0.48  (-4.1%)
Locilex
Mild infections of diabetic foot ulcers
Phase 3
Phase 3 top-line data are due September 2016
DRRX
$1.85
-0.01  (-0.54%)
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 1b
Phase 1b data due 3Q 2016
ESPR
$11.29
+0.11  (+0.98%)
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 2
Phase 2 (PK/PD) top-line data September 3Q 2016
FOLD
$7.37
+0.17  (+2.36%)
Migalastat HCl monotherapy (012)
Fabry Disease
Phase 3
NDA Filing delayed following meeting with FDA. Expects to meet with FDA in 3Q 2016 to discuss path forward
GNCA
$5.33
+0.09  (+1.72%)
GEN-003
Genital herpes
Phase 2b
Phase 2 12 month data released March 2016. Phase 2b virologic efficacy data due September 2016. 6-month efficacy data due late 2016
GWPH
$85.04
+0.66  (+0.78%)
Epidiolex
Lennox-Gastaut syndrome (LGS)
Phase 3
First Phase 3 trial data released June 2016. Data from second Phase 3 trial due towards and of 3Q 2016
INFI
$1.68
-0.06  (-3.45%)
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 3
Phase 3 top-line data due 4Q 2016
KERX
$4.69
+0.27  (+6.11%)
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients
sNDA Filing
Phase 3 top line data released late March 2016. sNDA to be filed late 3Q 2016
KITE
$60.33
-0.9  (-1.47%)
KTE-C19 (ZUMA-1)
Refractory Non-Hodgkin’s Lymphoma (NHL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Top-line data due late 3Q 2016 with BLA filing due late 2016
KMDA
$4.53
+0.05  (+1.12%)
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2
Top-line data due 3Q 2016
KPTI
$7.82
+0.06  (+0.77%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2
Phase 2 top-line data due September 2016
MESO
$5.57
-0.05  (-0.89%)
MPC-300-IV
Rheumatoid arthritis
Phase 2
Phase 2 data from both two cohorts due 3Q 2016
MRNS
$1.61
-0.09  (-5.29%)
Ganaxolone
PCDH19
Phase 2
Phase 2 data due 3Q 2016
MSTX
$0.42
+0  (+0.26%)
ANX-188 - Vepoloxamer
Sickle cell disease
Phase 3
Phase 3 data due in September 2016
NVAX
$7.40
+0.17  (+2.35%)
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3
Phase 3 data due 3Q 2016
OGXI
$0.60
+0.02  (+3.77%)
Custirsen in combination with Jevtana (cabazitaxel)- AFFINITY
Castrate-resistant prostate second-line - cancer
Phase 3
Phase 3 final data due 3Q 2016 but noted that a subpopulation who had multiple poor prognostic risk factors did NOT show improvement in survival
RPRX
$2.11
+0.02  (+0.96%)
Enclomiphene
Secondary hypogonadism
Phase 2
Phase 2 6-month data released August 2016
RTRX
$16.98
-0.1  (-0.59%)
Sparsentan (DUET)
Focal segmental glomerulosclerosis (FSGS)
Phase 2
Phase 2 top-line data due 3Q 2016
THLD
$0.97
-0.05  (-4.91%)
Tarloxotinib
Cancer - mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer
Phase 2
Phase 2 initiated August 2015. Prelim data due 3Q 2016
THLD
$0.97
-0.05  (-4.91%)
Tarloxotinib
Cancer - Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
Phase 2
Phase 2 initiated August 2015. Prelim data due 3Q 2016
TNXP
$2.69
-0.03  (-1.11%)
TNX-102 SL
Fibromyalgia
Phase 3
Phase 3 data due 3Q 2016. Second Phase 3 trial initiated July 2016
VICL
$4.10
-0.06  (-1.44%)
ASP0113 Vaccine
Kidney transplant recipients
Phase 2
Initiated Phase 2 Dec 2013. Data due 3Q 2016
VRTX
$100.99
+0.03  (+0.03%)
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
PDUFA
PDUFA September 30 2016
CERU
$1.12
-0.02  (-1.75%)
CRLX101 and paclitaxel
Platinum-resistant ovarian cancer
Phase 2
Further interim data due at the 2016 European Society for Medical Oncology (ESMO) Congress 7-11 October 2016
CLDX
$3.78
-0.12  (-3.08%)
Glembatumumab vedotin
Cancer - melanoma
Phase 2
Phase 2 initiated December 2014. Data to be at the European Society for Medical Oncology (ESMO) Congress in October 2016
EGLT
$8.94
+0.6  (+7.19%)
Egalet-001
Abuse-Deterrent Morphine
PDUFA
PDUFA October 14 2016. Advisory Committee Meeting August 4 2016 voted 18 to 1 to recommend approval
WINT
$2.64
-0.08  (-2.94%)
Aerosurf
Respiratory Distress Syndrome
Phase 2a
Phase 2a data due in late September or early October 2016
MDVN
$80.27
-0.15  (-0.19%)
XTANDI
metastatic Castrate-resistant Prostate Cancer (CRPC)
PDUFA
PDUFA for sNDA October 22, 2016
PRQR
$5.94
+0.5  (+9.19%)
QR-010
Cystic Fibrosis
Phase 1b
Phase 1b enrolment started June 2015. Preliminary data due at the North American Cystic Fibrosis Conference (NACFC) October 27 - 29, 2016
AMRN
$3.18
+0.03  (+0.95%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
Interim analysis due September or October 2016. Second interim analysis due 1H 2017
ANTH
$3.22
+0.03  (+0.94%)
Blisibimod
Lupus
Phase 3
Missed primary endpoints in Phase 2b trial Jun 2012. Phase 3 final data due early 4Q 2016
CYNA
$18.56
-0.34  (-1.8%)
APL-130277 - CTH-300
OFF episodes in patients with Parkinson’s disease
Phase 3
Phase 3 top-line data due towards end of 3Q or early 4Q 2016
INNL
$5.43
+0.03  (+0.56%)
Cogenzia
Diabetic foot ulcer infections
Phase 3
Data due early 4Q 2016
INNL
$5.43
+0.03  (+0.56%)
XaraColl
Post-operative pain
NDA Filing
NDA Filing due early 4Q 2016
OPXA
$4.69
+0.26  (+5.87%)
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
Phase 2b
Phase 2b initiated Sept 2012. Top-line data early 4Q 2016. October 31 estimate only for calendar entry.
PTN
$0.53
-0.01  (-0.08%)
Bremelanotide
Female sexual dysfunction (FSD)
Phase 3
Phase 3 initiated Dec 2014. Database lock late September 2016 with data due shortly after. October 31 BPC estimate only!
TBPH
$27.98
+0.93  (+3.44%)
Revefenacin
COPD
Phase 3
Phase 3 data due early 4Q 2016. October 31 estimate only for calendar purposes
THERF
$2.05
+0.05  (+2.72%)
Ibalizumab
Multi-drug resistant HIV-1
Phase 3
Phase 3 top-line released May 2016. 24 week treatment trial due to be completed by end of October 2016
EIGR
$16.75
+0.05  (+0.3%)
Lonafarnib - LOWR HDV – 2
Chronic hepatitis delta virus (HDV)
Phase 2
Phase 2 presentation at AASLD November 11-15 2016
EIGR
$16.75
+0.05  (+0.3%)
Lonafarnib - LOWR HDV – 4
Chronic hepatitis delta virus (HDV)
Phase 2
Phase 2 presentation at AASLD November 11-15 2016
EIGR
$16.75
+0.05  (+0.3%)
Lonafarnib - LOWR HDV – 3
Chronic hepatitis delta virus (HDV)
Phase 2
Phase 2 presentation at AASLD November 11-15 2016
LXRX
$15.45
-0.11  (-0.71%)
Telotristat etiprate
Carcinoid Syndrome
PDUFA priority review
PDUFA November 30, 2016 under priority review
BLUE
$54.91
+0.2  (+0.37%)
LentiGlobin
β-Thalassemia
Phase 1/2
Update expected at ASH December 2016
BLUE
$54.91
+0.2  (+0.37%)
LentiGlobin - HGB-206
Sickle disease
Phase 1/2
Update expected at ASH December 2016
SPPI
$5.99
-0.04  (-0.66%)
Apaziquone
Bladder cancer
PDUFA
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016
DVAX
$16.85
+0.11  (+0.66%)
HEPLISAV-B
Hepatitis B
PDUFA
CRL Feb 25 2013. New PDUFA for BLA orginally set for September 15 2016 has been delayed until December 15 2016. Vaccines and Related Biological Products Advisory Committee to discuss filing on November 16, 2016.
CEMP
$22.85
+0.21  (+0.93%)
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
PDUFA
PDUFA December 27 2016
AAAP
$33.22
+0.5  (+1.53%)
Lutathera
Inoperable progressive midgut NETs
PDUFA
PDUFA date under priority review December 28, 2016
CEMP
$22.85
+0.21  (+0.93%)
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
PDUFA
PDUFA December 28 2016
BLRX
$0.86
-0.02  (-2.15%)
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2
Phase 2 trial initiated March 2016. Partial data due by end of 2016 with topline data due by the end of 2017
ACAD
$34.36
+0.04  (+0.12%)
Pimavanserin
Alzheimer’s disease psychosis
Phase 2
Phase 2 top-line data due 4Q 2016
ACHN
$9.22
-0.08  (-0.75%)
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2
Phase 2 interim data due by end of 2016
ACOR
$25.62
-0.32  (-1.23%)
Dalfampridine
Post stroke deficits
Phase 3
Phase 3 data due 2H 2016
ACRS
$21.24
+0.44  (+2.12%)
A-101
Seborrheic keratosis (SK)
Phase 3
Phase 3 data due 4Q 2016
ACRX
$3.50
+0.05  (+1.45%)
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery
Phase 3
CRL Jul 26 2014. Additional clinical trial required. NDA Filing due by end of 2016
ADHD
$5.06
+0.21  (+4.33%)
MDX (Metadoxine Extended Release (MG01CI))
Adult ADHD
Phase 3
Data from second Phase 3 trial due by end of 2016
ADMS
$14.30
+0.19  (+1.35%)
ADS-5102 - EASE LID trial
Levodopa-Induced Dyskinesia
NDA Filing
Phase 3 data released December 2015. NDA filing due 2016
ADRO
$15.26
+0.13  (+0.86%)
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Phase 2b
Phase 2b interim data to be released 2H 2016
AEZS
$3.67
+0  (+0%)
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3
CRL Nov 5 2014. Initiated Phase 3 trial in November 2015, to be completed 2016
AEZS
$3.67
+0  (+0%)
Zoptrex
Endometrial cancer
Phase 3
Phase 3 trial to be completed 2016
AGRX
$7.33
+0.28  (+4.12%)
Twirla
Contraceptive patch
Phase 3
CRL issued 2013. Phase 3 to be completed 4Q 2016.
ALKS
$46.50
+1.14  (+2.54%)
ALKS 5461
Major depressive disorder
Phase 2
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials, due by end of 2016
ALNY
$75.79
-0.39  (-0.51%)
ALN-TTRsc02
ATTR amyloidosis
Phase 1
Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016
ANTH
$3.22
+0.03  (+0.94%)
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3
Phase 3 initiated October 2015. Top-line data due 4Q 2016
APRI
$0.36
-0.03  (-5.44%)
Vitaros
Erectile dysfunction
NDA Filing
NDA to be resubmitted at earliest late 4Q 2016
ARDM
$4.70
-0.09  (-1.88%)
Pulmaquin - ORBIT-3 and ORBIT-4
Non-cystic fibrosis bronchiectasis (non-CF BE).
Phase 3
Phase 3 data due by the end of 2016
ARGS
$4.47
+0.17  (+3.95%)
AGS-003
Early stage renal cell carcinoma (RCC) - cancer
Phase 2
Phase 2 initial data due 4Q 2016
ARIA
$10.60
+0.04  (+0.38%)
Iclusig (ponatinib)
Cancer - third line chronic-phase CML (CP-CML)
Phase 2
Phase 2 dose ranging trial initiated August 2015. Preliminary data due end of 2016
ARNA
$1.68
+0  (+0%)
APD334
Ulcerative colitis
Phase 2
Phase 2 data due 4Q 2016
AVIR
$1.42
+0.02  (+1.43%)
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2b
Phase 2b top-line data due 2H 2016
AXON
$16.50
+0.25  (+1.54%)
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 2
Phase 2 data due 2H 2016
BDSI
$2.84
+0.04  (+1.43%)
Clonidine gel
Painful diabetic neuropathy (PDN)
Phase 2b
Phase 3 trial failed to meet primary endpoint late March 2015. New trial initiated late 2015. Data due from Phase 2b trial 4Q 2016
BLPH
$1.67
+0.04  (+2.45%)
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2
Phase 2 to be initiated 3Q 2016. Data due by end of 2016
CASC
$1.17
-0.02  (-1.68%)
ONT-380 and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 1b
Phase 1b updated data released at ASCO 2016. Further data due by end of 2016
CATB
$4.98
-0.02  (-0.4%)
CAT-1004
Duchenne muscular dystrophy (DMD)
Phase 2
Phase 2 data due late 2016
CCXI
$4.61
-0.03  (-0.65%)
CCX872
Non-resectable pancreatic cancer
Phase 1b
Phase 1b early response data due mid 2016. Initial PFS data due 2H 2016
CCXI
$4.61
-0.03  (-0.65%)
CCX168
atypical Hemolytic Uremic Syndrome (aHUS)
Phase 2
Phase 2 data due 2016
CEMP
$22.85
+0.21  (+0.93%)
Solithromycin
NASH
Phase 2
Phase 2 interim data due 4Q 2016
CERC
$4.01
-0.12  (-2.91%)
CERC-501
Smoking cessation
Phase 2
Phase 2 top-line data due 4Q 2016
CERU
$1.12
-0.02  (-1.75%)
CRLX101 in Combination with Chemotherapy and Radiation
Renal Cell Carcinoma cancer
Phase 2
Initial data released mid March 2015. Further interim data due 2H 2016
CHRS
$29.89
-0.32  (-1.06%)
CHS-1420
Psoriasis
Phase 3
Phase 3 top-line data met endpoints August 2016. Full data due 4Q 2016 with BLA filing to follow.
CLBS
$5.37
-0.05  (-0.92%)
CLBS03
Type 1 diabetes
Phase 2
Phase 2 initiated March 2016. Interim data due by the end of 2016
CORI
$5.29
+0.06  (+1.14%)
Twirla
Contraceptive patch
Phase 3
CRL issued 2013. Phase 3 to be completed 4Q 2016.
CRBP
$3.88
-0.06  (-1.52%)
Resunab
Cystic Fibrosis
Phase 2
Phase 2 data due 4Q 2016
CRBP
$3.88
-0.06  (-1.52%)
Resunab
Systemic Sclerosis
Phase 2
Phase 2 data due 4Q 2016
CRMD
$1.60
-0.09  (-5.33%)
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3
Phase 3 enrolment to be completed in 2016. Interim analysis due 4Q 2016 with Phase 3 data due 3Q 2017
CTRV
$1.15
+0  (+0%)
CMX157
Hepatitis B
Phase 2
Phase 2 dosing initiated June 2016. Trial to be completed 4Q 2016
CYCC
$7.42
-0.86  (-10.39%)
Sapacitabine (SEAMLESS)
Acute myeloid leukemia - cancer
Phase 3
Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data due around 4Q 2016
CYTR
$0.59
-0.01  (-0.99%)
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 3
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis due 4Q 2016
CYTR
$0.59
-0.01  (-0.99%)
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 2
Phase 2 overall survival data due 2H 2016. Updated interim data at ASCO 2016
CYTR
$0.59
-0.01  (-0.99%)
Aldoxorubicin
Relapsed/refractory small cell lung cancer
Phase 2a
Phase 2b data due 4Q 2016
DMTX
$6.26
+0.2  (+3.3%)
DTX101
hemophilia B
Phase 1/2
Phase 1/2 initial data due 2H 2016
DRNA
$3.68
-0.04  (-1.08%)
DCR-MYC
Hepatocellular carcinoma (HCC) - cancer
Phase 1/2
Phase 1b/2 preliminary data due by the end of 2016
EARS
$2.03
+0.01  (+0.5%)
AM-101 - TACTT3
Acute inner ear tinnitus
Phase 3
Phase 3 enrolment completed June 2016 with topline data due 4Q 2016
EIGR
$16.75
+0.05  (+0.3%)
Subcutaneous exendin
Hypoglycemia post-gastric bypass surgery
Phase 2
Phase 2 data due by the end of 2016
EXEL
$11.61
+0.17  (+1.49%)
Recurrent endometrial cancer
Recurrent endometrial cancer
Phase 2
Phase 2 data due 2016
FLXN
$17.86
-0.15  (-0.78%)
Zilretta - FX006
Osteoarthritis of the knee
NDA Filing
NDA to be filed 4Q 2016
FOLD
$7.37
+0.17  (+2.36%)
ATB200
Pompe Disease
Phase 1/2
Phase 2 interim data due 2H 2016
FOMX
$8.80
+0  (+0%)
FDX103
Papulopustular rosacea
Phase 2
Phase 2 initiated October 2015. Enrolment completed May 2016. Top-line data due by the end of 2016
GALE
$0.45
+0.01  (+3.11%)
NeuVax in combination with Herceptin
Breast cancer
Phase 2b
Phase 2b interim safety data due 4Q 2016
GBIM
$0.88
+0  (+0%)
GS-4774 - 1401 trial
Chronic hepatitis B infection
Phase 2
Phase 2 initiated by GILD in 2014. 24 week data showed no statistical improvement - May 2016. 48-week results are expected to be available 2H 2016.
GBIM
$0.88
+0  (+0%)
GI-6207
Cancer - MTC (medullary thyroid cancer)
Phase 2
Phase 2 data due 2H 2016
GTXI
$0.60
+0.03  (+5.26%)
Enobosarm
Breast cancer - advanced ARTNBC
Phase 2
Phase 2 prelim data due by end of 2016
GTXI
$0.60
+0.03  (+5.26%)
Enobosarm
Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer
Phase 2
Phase 2 prelim data due by end of 2016
GWPH
$85.04
+0.66  (+0.78%)
Epidiolex
Dravet Syndrome
Phase 3
Second Phase 3 trial initiated mid April 2015. Topline data due 2H 2016
GWPH
$85.04
+0.66  (+0.78%)
Sativex
Multiple Sclerosis (MS) spasticity
Phase 2
Phase 2 data due 4Q 2016
HALO
$10.10
-0.2  (-1.94%)
PEGPH20
Pancreatic cancer
Phase 2
Phase 3 dosing initiated March 2016. Phase 2 PFS data due 4Q 2016
HRTX
$20.88
-0.13  (-0.62%)
HTX-019
Prevention of chemotherapy-induced nausea and vomiting (CINV)
NDA Filing
NDA filing due 4Q 2016
HTBX
$1.63
+0.09  (+5.84%)
HS-410
Bladder cancer
Phase 2
Phase 2 data due 4Q 2016.
HTBX
$1.63
+0.09  (+5.84%)
HS-110
Non-small cell lung cancer (NSCLC)
Phase 1b
Phase 1b topline data due 4Q 2016
HZNP
$22.39
-0.15  (-0.67%)
ACTIMMUNE
Friedreich’s Ataxia (FA)
Phase 3
Phase 3 data due by the end of 2016
IDRA
$1.95
+0.02  (+1.04%)
IMO-2125
Cancer - melanoma
Phase 1/2
Phase 1/2 trial initiated December 2015. Initial data due 2H 2016
IMGN
$3.14
+0.03  (+0.96%)
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Phase 3
Phase 3 data due 2016
INCY
$81.90
-0.08  (-0.1%)
Ruxolitinib
Breast Cancer
Phase 2
Phase 2 data due 2016
INSY
$16.37
+0.4  (+2.5%)
Buprenorphine
Acute pain in patients undergoing a bunionectomy procedure
Phase 3
Phase 3 data due 2016.
IONS
$33.71
-0.16  (-0.47%)
IONIS-FXIRx
End-stage renal disease
Phase 2
Phase 2 data due 2016
IONS
$33.71
-0.16  (-0.47%)
IONIS-STAT3-2.5Rx
Cancer
Phase 2
Phase 2 data due 2016
IRWD
$13.97
+0.17  (+1.23%)
Linaclotide Colonic Release
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2b
Phase 2b data due 2H 2016
ITCI
$41.96
+0.97  (+2.37%)
ITI-007-302
Schizophrenia
Phase 3
Phase 3 enrolment completed June 2016. Data due later in 2016.
ITEK
$6.99
-0.01  (-0.15%)
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 3
Phase 3 initiated October 2015. Top-line data due 4Q 2016
KPTI
$7.82
+0.06  (+0.77%)
Selinexor - STOMP
Multiple myeloma
Phase 1/2
Phase 1/2 data due late 2016
KPTI
$7.82
+0.06  (+0.77%)
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2
Phase 2 initiated June 25 2014. Preliminary topline data due late 2016 with top-line data due mid 2017
KTOV
$3.13
-0.03  (-0.95%)
KIT-302
Osteoarthritis and Hypertension
NDA Filing
NDA Filing to be submitted by the end of 2016
KURA
$5.49
+0.41  (+8.07%)
Tipifarnib
HRAS mutant solid tumors - cancer
Phase 2
Phase 2 top-line data due 2H 2016
LIFE
$3.25
+0  (+0%)
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B
Phase 1/2
Phase 1b/2 data due 4Q 2016
MATN
$0.70
+0.02  (+2.64%)
OXi4503
Acute myeloid leukemia (AML)
Phase 1/2
Initiated October 2015. Data due 2016
MATN
$0.70
+0.02  (+2.64%)
CA4P Fosbretabulin
Cancer - gastrointestinal neuroendocrine tumors
Phase 2
Phase 2 initiated Sept 2014. Interim data released October 2015. Full data due 2H 2016
MDGN
$5.80
+0.08  (+1.4%)
NFC-1
mGluR mutation positive ADHD
Phase 2/3
Phase 2/3 initiated June 2016. Initial top-line data are due 2H 2016
MDVN
$80.27
-0.15  (-0.19%)
Enzalutamide
Estrogen receptors and progesterone receptors (ER/PgR)+ BC - cancer
Phase 2
Phase 2 data due 2H 2016
MNOV
$6.55
+0.08  (+1.24%)
Progressive multiple sclerosis (progressive MS)
Progressive multiple sclerosis (progressive MS)
Phase 2b
Enrolment completed May 2015. Interim analysis due 4Q 2016
MRUS
$9.12
-0.08  (-0.87%)
MCLA-128
Breast cancer
Phase 1/2
Phase 1/2 interim data due by the end of 2016
MRUS
$9.12
-0.08  (-0.87%)
MCLA-117
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2 interim data due by the end of 2017
NBIX
$51.50
-0.03  (-0.05%)
NBI-98854 (Valbenazine)
Tourette syndrome
Phase 2
Phase 2 data due by end of 2016
NDRM
$17.38
+0.04  (+0.23%)
ND0612H
Severe Parkinson’s Disease
Phase 2
Phase 2 to be completed 2H 2016
NKTR
$18.16
+0.33  (+1.85%)
Cipro DPI
Bronchiectasis
Phase 3
Phase 3 data due 2H 2016
NKTR
$18.16
+0.33  (+1.85%)
NKTR-214
Solid tumors - cancer
Phase 1/2
Phase 1/2 initial topline data due 2H 2016
NVAX
$7.40
+0.17  (+2.35%)
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2
Phase 2 data due by end of 2016
NVCR
$7.91
-0.08  (-0.88%)
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer
Phase 2
Phase 2 data due late 2016
OCUL
$6.88
-0.15  (-2.13%)
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3
Phase 3 data due 4Q 2016
OGXI
$0.60
+0.02  (+3.77%)
Apatorsen Borealis-2
Advanced or metastatic bladder cancer
Phase 2
Phase 2 initiated Apr 2013. Data due 4Q 2016
ONCE
$58.09
-0.26  (-0.45%)
SPK-CHM
Choroideremia
Phase 1/2
Phase 1/2 dosing commenced 1Q 2015. Initial data due 2H 2016
ONCE
$58.09
-0.26  (-0.45%)
SPK-RPE65
Inherited retinal dystrophies
BLA Filing
BLA filing due 2H 2016
OPHT
$54.92
+1.19  (+2.21%)
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 3
Phase 3 data due 2H 2016
OPK
$9.52
-0.29  (-2.86%)
hGH-CTP
Adults - growth hormone deficiency
Phase 3
Initiated Phase 3 Jun 2013. Phase 3 data 2H 2016
OTIC
$17.26
-0.05  (-0.29%)
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2
Second Phase 2 trial initiated March 2016. Due to be completed 4Q 2016
PBYI
$56.62
+1.97  (+3.6%)
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2
Phase 2 data due 4Q 2016
PBYI
$56.62
+1.97  (+3.6%)
Neratinib monotherapy with high dose loperamide prophylaxis
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 2
Phase 2 addtional data due 2016
PGNX
$6.84
-0.13  (-1.87%)
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Phase 3
Phase 3 interim analysis due 4Q 2016
PLX
$0.61
-0.02  (-2.27%)
PRX-110
Cystic Fibrosis
Phase 2
Phase 2 initiated July 2016. Data are due by end of 2016
PLX
$0.61
-0.02  (-2.27%)
PRX-106
Ulcerative Colitis
Phase 2
Phase 2 data due around the end of 2016
PRTO
$9.66
+0.02  (+0.21%)
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3
Phase 3 initiated July 2014. Data due December 2016
PTLA
$20.05
+0.83  (+4.32%)
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
NDA Filing
Phase 3 data released late March 2016 did not show superiority against standard of care. Company still intends to file NDA in 2H 2016
PTLA
$20.05
+0.83  (+4.32%)
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Phase 2
Phase 2 enrolment commenced May 2016. Data due later in 2016
RARE
$69.36
+1.26  (+1.85%)
KRN23
Tumor-induced osteomalacia (TIO)
Phase 2
Interim data released April 2016. Additional data due 2H 2016
RARE
$69.36
+1.26  (+1.85%)
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2
Phase 2 initiated March 2014. Seizure data due 2H 2016
RARE
$69.36
+1.26  (+1.85%)
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Phase 3
Phase 2 interim data released October 2015. Further data due 2H 2016. Phase 3 planned for 2017
RDHL
$15.40
+0.04  (+0.26%)
RIZAPORT (RHB-103)
Migraine
NDA Filing
Planned resubmission of NDA due 4Q 2016
RDHL
$15.40
+0.04  (+0.26%)
RHB-104 MAP US
Crohn’s disease
Phase 3
Phase 3 safety and futility analysis due 2H 2016
RDHL
$15.40
+0.04  (+0.26%)
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2a
Phase 2a data due 4Q 2016
REPH
$9.78
+1.18  (+13.72%)
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
Phase 3
Two Phase 3 trial initiated January 2016. Top-line data from first trial released July 2016. Data from second trial due by end of 2016
RIGL
$2.88
+0.07  (+2.49%)
Fostamatinib
IgA nephropathy
Phase 2
Phase 2 data due by the end of 2016
RNN
$0.27
+0  (+0.37%)
Supinoxin
Triple negative breast cancer and platinum resistant ovarian cancer
Phase 1/2
Phase 1/2 to be initiated 2H 2016 with interim data also due 2H 2016
RNN
$0.27
+0  (+0.37%)
RX-3117
Relapsed and refractory pancreatic cancer and advanced bladder cancer.
Phase 1/2
Phase 1b/2 trial initiated March 2016. Interim data to be released 2016
RPRX
$2.11
+0.02  (+0.96%)
Proellex
Uterine fibroids (vaginal treatment)
Phase 2b
Phase 2b complete second course of treatment 2H 2016
RPRX
$2.11
+0.02  (+0.96%)
Proellex
Endometriosis
Phase 2
Phase 2 data due 2H 2016
RVNC
$15.51
+0.37  (+2.44%)
RT002
Cervical dystonia
Phase 2
Phase 2 initiated September 2015. Further data to be released 2H 2016
RXII
$2.40
+0.03  (+1.27%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2
Phase 2 preliminary data due 2H 2016
RXII
$2.40
+0.03  (+1.27%)
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2
Phase 2 preliminary data due 2H 2016
RXII
$2.40
+0.03  (+1.27%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2
Phase 2 preliminary data due 2H 2016
RXII
$2.40
+0.03  (+1.27%)
RXI-109-1501
Retinal scarring
Phase 1/2
Phase 2 preliminary data due 2H 2016
SAGE
$38.16
+0.5  (+1.33%)
SAGE-547
SRSE
Phase 3
Phase 3 data due 1H 2017
SCMP
$11.49
+0  (+0%)
Lubiprostone
Pediatric functional constipation
Phase 3
Phase 3 data due 2H 2016, with two more Phase 3 trials to be initiated in 2017
SGYP
$5.05
-0.17  (-3.26%)
Plecanatide
Constipation-predominant irritable bowel syndrome (IBS-C).
Phase 3
Phase 3 data due 4Q 2016
SNGX
$0.59
+0  (+0.85%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3
Phase 3 data due 2H 2016
TCON
$6.60
+0.01  (+0.15%)
TRC105 and Avastin
Glioblastoma - cancer
Phase 2
Phase 2 data due by end of 2016
TENX
$2.40
-0.03  (-1.23%)
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery
Phase 3
Phase 3 top line data due 4Q 2016.
VSAR
$13.18
+0.09  (+0.69%)
VRS-317 VITAL
Growth hormone deficiency, or GHD - adult
Phase 2/3
Phase 2 trial initiated September 2015. Data due 2H 2016
VTAE
$7.65
-0.1  (-1.29%)
VTP-38543
Atopic dermatitis
Phase 2
Phase 2 initiated December 2015. Topline data due 4Q 2016
VTVT
$5.66
-0.04  (-0.7%)
TTP273 - LOGRA
Type 2 Diabetes
Phase 2
Phase 2 initiated January 2016. Topline results are expected at the end of 2016.
VYGR
$13.76
-0.52  (-3.64%)
VY-AADC01
Advanced Parkinson’s disease
Phase 1b
Phase 1b trial onoging. Topline data due 4Q 2016
XENT
$15.42
+0.36  (+2.39%)
RESOLVE steroid-releasing implant
Recurrent sinus obstruction
Phase 3
Phase 3 preliminary top-line data due 4Q 2016
XLRN
$30.91
+0.14  (+0.45%)
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 2
Phase 2 initial data due by end of 2016
XLRN
$30.91
+0.14  (+0.45%)
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 continues to enrol as of late February 2016. Preliminary data potentially due year end 2016
XOMA
$0.60
+0  (+0.31%)
XOMA 358
Congenital hyperinsulinism
Phase 2
Phase 2 initiated October 2015. Data are due in 2016
VCEL
$2.36
+0.09  (+3.96%)
MACI
Focal chondral cartilage defects in the knee.
PDUFA
PDUFA date January 3 2017
TSRO
$92.76
-6.33  (-6.39%)
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
PDUFA
PDUFA January 11 2017
INCY
$81.90
-0.08  (-0.1%)
Baricitinib
Rheumatoid arthritis
PDUFA
Announced January 19 2016 that their NDA Filing has been submitted by partner Eli Lilly
BMRN
$99.43
+1.26  (+1.28%)
Cerliponase alfa
Batten Disease
PDUFA
PDUFA date January 27 2017
SGYP
$5.05
-0.17  (-3.26%)
Plecanatide
Chronic idiopathic constipation (CIC)
PDUFA
PDUFA January 29 2017
BTX
$3.14
-0.06  (-1.87%)
AST-OPC1
Cervical spinal cord injury
Phase 1/2
Phase 1/2 topline data due January 2017
SMMT
$7.15
-0.1  (-1.38%)
Ezutromid
Duchenne muscular dystrophy
Phase 2
Phase 2 24-week data due January 2017
CLVS
$23.03
+4.93  (+27.24%)
Rucaparib ARIEL2
Cancer - ovarian second line
PDUFA priority review
PDUFA date under priority review February 23, 2017
ACOR
$25.62
-0.32  (-1.23%)
CVT-301
OFF episodes of Parkinson’s disease (PD)
Phase 3
Phase 3 data due 1Q 2017
AFMD
$2.78
+0.02  (+0.72%)
AFM13
Hodgkin Lymphoma - Cancer
Phase 1b
Phase 1b update due end of 2016 or early 2017
AKAO
$3.83
+0.02  (+0.52%)
Plazomicin - EPIC trial
Complicated urinary tract infections (cUTI)
Phase 3
Phase 3 top-line results due 1Q 2017
ARDX
$10.00
-0.06  (-0.6%)
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3
Phase 3 data due 1Q 2017
ARQL
$1.48
-0.04  (-2.63%)
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 3
Phase 3 SPA agreed upon. Dosage reduced following recommendation from DMC. Final analysis late 2016 or early 2017
BMRN
$99.43
+1.26  (+1.28%)
PEG-PAL
Phenylketonuria (PKU)
BLA Filing
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 4Q 2016 or 1Q 2017
CAPR
$3.74
+0.14  (+3.98%)
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 1/2
Phase 1/2 data due 1Q 2017
CAPR
$3.74
+0.14  (+3.98%)
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)
Phase 2
Phase 2 enrolling. 6 month data due 1Q 2017
DERM
$33.89
+0.86  (+2.6%)
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3
Phase 3 data due 4Q 2016 or 1Q 2017
EYEG
$1.83
+0.04  (+2.23%)
EGP-437
Non-infectious anterior uveitis
Phase 3
Phase 3 enrolment commenced January 2016. Top-line data due 1Q 2017
FGEN
$19.11
+0.06  (+0.31%)
FG-3019
Pancreatic cancer
Phase 2
Phase 2 ongoing. Data due early 2017
FOLD
$7.37
+0.17  (+2.36%)
SD-101
Epidermolysis Bullosa (EB)
Phase 3
Phase 3 top-line data due 4Q 2016 or 1H 2017 ”
KPTI
$7.82
+0.06  (+0.77%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b
Phase 2b initiated Dec 2014. Preliminary topline data due early 2017
LJPC
$19.05
+0.19  (+1.01%)
LJPC-501
Catecholamine-resistant hypotension (CRH)
Phase 3
Phase 3 data due 1Q 2017
MDCO
$39.58
+1.12  (+2.94%)
CARBAVANCE
Complicated urinary tract infections (cUTI)
NDA Filing
Phase 3 data met endpoints June 2016. NDA filing due early 2017
NKTR
$18.16
+0.33  (+1.85%)
NKTR-181
Lower back pain
Phase 3
Phase 3 initiated late Feb 2015. Data due 1Q 2017
NKTR
$18.16
+0.33  (+1.85%)
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3
Phase 3 data due early 2017
OCRX
$2.40
+0  (+0%)
OCR-002 (IV)
Hepatic encephalopathy
Phase 2b
Phase 2b trial to complete enrolment 4Q 2016. Data due 1Q 2017
OGXI
$0.60
+0.02  (+3.77%)
Apatorsen and Zytiga - Pacific trial
Chemotherapy-naive patients with metastatic CRPC - cancer
Phase 2
Phase 2 data due early 2017
OMED
$10.73
+0.25  (+2.39%)
Tarextumab - PINNACLE trial
Small cell lung cancer
Phase 2
Data due late 2016 or early 2017
OPK
$9.52
-0.29  (-2.86%)
Factor VIIa-CTP
Hemophilia
Phase 2
Phase 2 data due late 2016 or early 2017
PBMD
$0.86
+0.01  (+1.82%)
Tarextumab plus platinum chemotherapy and etoposide
First-line extensive-stage small cell lung cancer
Phase 2
Phase 2 data due early 2017
PBYI
$56.62
+1.97  (+3.6%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3
Phase 3 data due 4Q 2016 or 1Q 2017
PGNX
$6.84
-0.13  (-1.87%)
Azedra
Pheochromocytoma
Phase 2b
Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Enrolment completed by end of 2015.Top-line data due between December 2016 and March 2017
PRTO
$9.66
+0.02  (+0.21%)
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3
Phase 3 enrolment to be completed 1Q 2017
PTCT
$8.29
-0.01  (-0.12%)
Translarna
Nonsense mutation cystic fibrosis
Phase 3
Phase 3 initiated July 2014. Enrolment completed November 2015. Data due early 2017
QURE
$8.44
-0.44  (-4.95%)
AMT-060
Sanfilippo B
Phase 1/2
Phase 1/2 30 month follow up data 1Q 2017
RDUS
$56.74
-0.7  (-1.22%)
Abaloparatide-SC
Osteoporosis
PDUFA
Announced May 31 2016 that their NDA filing had been accepted for review by FDA
RIGL
$2.88
+0.07  (+2.49%)
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 2
Phase 2 data from first of two stages due early 2017
RTTR
$1.30
-0.03  (-2.26%)
RP-G28
Lactose intolerance
Phase 2/3
Phase 2/3 initiated March 2016. Enrollment completed August 2016. Top-line data are due 1Q 2017
SUPN
$22.75
+0.51  (+2.29%)
SPN-812
ADHD
Phase 2b
Phase 2b data due early 2017
SYN
$1.69
+0  (+0%)
SYN-004
C. difficile Infection
Phase 2b
Phase 2b initiated September 2015. Topline data due 1Q 2017
TRVN
$7.42
+0  (+0%)
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 3
Phase 3 APOLLO-1 and APOLLO-2 commenced June 2016. Top-line data 1Q 2017.
WINT
$2.64
-0.08  (-2.94%)
Aerosurf
Respiratory Distress Syndrome
Phase 2b
Phase 2b enrolment to be completed by the end of 2016. Top-line data due 1Q 2017.
XENE
$7.86
-0.11  (-1.44%)
XEN801
Acne
Phase 2
Phase 2 initiated February 2016. Data due 1Q 2017
ZGNX
$9.56
-0.04  (-0.42%)
ZX008
Dravet syndrom
Phase 3
Second Phase 3 trial initiated June 2016. Phase 3 data due 1Q 2017
ZSAN
$1.14
-0.01  (-0.87%)
ZP-Triptan
Migraine
Phase 3
Pivotal trial to be completed 1Q 2017
IMDZ
$7.05
-0.02  (-0.29%)
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2
Phase 2 potential data at ASCO 2017
IMDZ
$7.05
-0.02  (-0.29%)
CMB305
Cancer - solid tumors
Phase 2
Phase 2 potential data at ASCO 2017
ABIO
$2.97
-0.06  (-1.98%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b
Phase 2b interim analysis due 2Q 2017
AKAO
$3.83
+0.02  (+0.52%)
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)
Phase 3
Phase 3 topline data due 1H 2017
ALDR
$33.31
+0  (+0%)
ALD403 - PROMISE 1
Frequent episodic migraine
Phase 3
Phase 3 topline data due 1H 2017. PROMISE 2 trial to be initiated 2H 2016
ALNY
$75.79
-0.39  (-0.51%)
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3
Phase 3 data due mid 2017
ARDX
$10.00
-0.06  (-0.6%)
RDX227675
Hyperkalemia
Phase 3
Onset-of-action and Phase 3 trials to be initiated 4Q 2016 with data due 1H 2017 from onset-of-action trial.
ARGS
$4.47
+0.17  (+3.95%)
AGS-003 ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 3
Phase 3 overall survival analysis due 1H 2017
ARNA
$1.68
+0  (+0%)
Ralinepag
Pulmonary Arterial Hypertension
Phase 2
Phase 2 data due mid 2017
BVXV
$3.86
+0  (+0%)
M-001
Universal flu vaccine
Phase 2b
Phase 2b enrolment commenced March 2016. Data are due late 1H 2017
CEMP
$22.85
+0.21  (+0.93%)
Taksta
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3
Phase 3 initiated December 2015. Trial to be completed 1H 2017
CERC
$4.01
-0.12  (-2.91%)
CERC-301
Major depressive disorder (MDD)
Phase 2
Phase 2 data due 1H 2017
CERU
$1.12
-0.02  (-1.75%)
CRLX101, in combination with LYNPARZA
Solid tumors - cancer
Phase 1/2
Phase 1/2 trial commenced dosing May 2016. Top-line data due 1H 2017
CLCD
$8.50
-0.21  (-2.41%)
Lasmiditan - SPARTAN
Migraine
Phase 3
Phase 3 top-line data due mid 2017
CLVS
$23.03
+4.93  (+27.24%)
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
Phase 3
Pivotal trial initiated late 2013. Enrolment completed 2Q 2016. Data due 4Q 2017
CTIX
$1.35
-0.03  (-2.17%)
Cellceutix
Placque psoriasis
Phase 2
Phase 2b trial to be initiated late 3Q or early 4Q 2016. Data due 2Q 2017
CYNA
$18.56
-0.34  (-1.8%)
APL-130277 - CTH-301 Safety trial
OFF episodes in patients with Parkinson’s disease
Phase 3
Phase 3 top-line safety data due 1H 2017
CYTK
$12.13
-0.04  (-0.33%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2
Phase 2 initiated January 2016. Enrollment to be completed 2H 2016. Data are due 1H 2017
CYTX
$2.19
+0  (+0%)
ECCS-50
Scleroderma
Phase 3
Pivotal trial initiated August 2015. Enrolment completed June 2016. Data are due mid 2017
EGLT
$8.94
+0.6  (+7.19%)
Egalet-002
Moderate to severe chronic pain
Phase 3
Phase 3 ongoing. NDA planned for mid 2017
EGRX
$62.27
+2.36  (+3.94%)
AEB1102
Arginase I deficiency
Phase 1
Phase 1 to initated 1H 2016. Top-line data due 1H 2017
EPZM
$8.13
+0.07  (+0.87%)
Tazemetostat
Solid tumors - cancer
Phase 1b
Phase 2 data due 1H 2017
EPZM
$8.13
+0.07  (+0.87%)
Tazemetostat
Relapsed or refractory B-cell NHL
Phase 2
Phase 2 update at the American Society of Hematology (ASH) Meeting on Lymphoma Biology - June 18 2016. Futher data due 1H 2017
FBIO
$2.82
-0.02  (-0.7%)
Triplex vaccine
CMV control in allogeneic stem cell transplant recipients
Phase 2
Phase 2 data due 2Q 2017
FOMX
$8.80
+0  (+0%)
FMX101
Acne
Phase 3
Phase 3 dosing initiated May 2016. Data are due 1H 2017
GTXI
$0.60
+0.03  (+5.26%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2
Phase 2 initiated January 2016. Data are due 1H 2017
GWPH
$85.04
+0.66  (+0.78%)
GWP42006
Epilepsy
Phase 2
Phase 2 initiated May 2015. Data due 1H 2017
GWPH
$85.04
+0.66  (+0.78%)
Epidiolex
Dravet Syndrome
NDA Filing
Top line Phase 3 data released March 2016 met primary endpoint. NDA filing 1H 2017
ICPT
$167.07
+0.53  (+0.32%)
Obeticholic acid (OCA) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 3
Phase 3 interim analysis due 1H 2017
IDRA
$1.95
+0.02  (+1.04%)
IMO-8400
Waldenström’s Macroglobulinemia
Phase 1/2
Phase 2 data due 1H 2017
IDRA
$1.95
+0.02  (+1.04%)
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1/2
Phase 2 data due 1H 2017
IMGN
$3.14
+0.03  (+0.96%)
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 1/2
Phase 1b/2 initial data due 2Q 2017
IONS
$33.71
-0.16  (-0.47%)
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3
Phase 3 to be completed in 1H 2017
IONS
$33.71
-0.16  (-0.47%)
Nusinersen
CHERISH - Children with spinal muscular atrophy (SMA). ENDEAR trial - nusinersen in infants with spinal muscular atrophy SMA
Phase 3
Phase 3 CHERISH data due 1H 2017. Phase 3 ENDEAR trial met primary endpoint August 2016. Filing to be submitted.
KPTI
$7.82
+0.06  (+0.77%)
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2/3
Phase 2/3 trial initiated January 2016. Data from Phase 2 portion of trial due mid 2017
MDVN
$80.27
-0.15  (-0.19%)
Talazoparib - EMBRACA
BRCA-mutated breast cancer
Phase 3
Phase 3 data due 1H 2017
MDWD
$7.98
-0.18  (-2.21%)
NexoBrid
Severe burns
Phase 3
Phase 3 initiated mid April 2015. Data due 1H 2017
NVLS
$6.03
-0.06  (-0.99%)
N91115
Cystic Fibrosis
Phase 2
Phase 2 data from second trial due 1H 2017
OGXI
$0.60
+0.02  (+3.77%)
Custirsen ENSPIRIT
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3 initiated Oct 2012. First interim analysis released August 2014, second interim futility analysis July 2015. Data likely 1H 2017
OMED
$10.73
+0.25  (+2.39%)
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2
Phase 2 enrolment to be completed by end of 2016. Data are due 1H 2017
ONCE
$58.09
-0.26  (-0.45%)
SPK-8011
Hemophilia A
Phase 1/2
Phase 1/2 trial to be initiated 2H 2016 with initial data due 1H 2017
PRTK
$13.32
+0.21  (+1.6%)
Sarecycline
Severe acne vulgaris
Phase 3
Phase 3 data due 1H 2017
RARE
$69.36
+1.26  (+1.85%)
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Phase 3
Phase 3 enrolment completed July 2016. Data due 1H 2017
RETA
$17.86
+0.28  (+1.59%)
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2
Phase 2 initial data due 1H 2017
RETA
$17.86
+0.28  (+1.59%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2
Phase 2 initial data due 1H 2017
RPTP
$7.30
-0.06  (-0.82%)
RP 103
Mitochondrial disorders including Leigh syndrome
Phase 2
Phase 2 data due 1H 2017
SBPH
$11.48
-0.01  (-0.05%)
SB 9200
Hepatitis B (HBV)
Phase 2a
Phase 2a data due 1H 2017
TCON
$6.60
+0.01  (+0.15%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 1H 2017
VKTX
$1.28
-0.02  (-1.54%)
VK2809
Hypercholesterolemia
Phase 2
Phase 2 trial to commence August 2016. Trial to be completed 2Q 2017
VKTX
$1.28
-0.02  (-1.54%)
VK5211
Acute Hip Fracture
Phase 2
Phase 2 to be completed 2Q 2017
VNDA
$12.25
-0.24  (-1.92%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2
Phase 2 data due 1H 2017
VNDA
$12.25
-0.24  (-1.92%)
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis
Phase 2
Phase 2 data due 1H 2017
VRTX
$100.99
+0.03  (+0.03%)
VX-661
Two Copies of the F508del Mutation
Phase 3
Phase 3 trial to complete enrollment in August 2016, and data are expected in 1H 2017.
XENE
$7.86
-0.11  (-1.44%)
TV-45070
Postherpetic neuralgia
Phase 2b
Phase 2b initiated late March 2015. Data due 1H 2017
XNCR
$21.67
-0.09  (-0.41%)
XmAb5871
IgG4-Related Disease (IgG4-RD)
Phase 2
Phase 2 trial initiated March 2016. Initial data due 1H 2017
ZYNE
$7.30
+0  (+0%)
ZYN002
Fragile X syndrome
Phase 2
Phase 2 to be initiated 2H 2016. Data are due 1H 2017
ZYNE
$7.30
+0  (+0%)
ZYN002
Osteoarthritis
Phase 2
Phase 2 to be initiated 2H 2016. Data are due 1H 2017
ZYNE
$7.30
+0  (+0%)
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2
Phase 2 dosing commenced August 2016. Data are due 1H 2017
ARDX
$10.00
-0.06  (-0.6%)
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3
Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due later that year
FGEN
$19.11
+0.06  (+0.31%)
FG-3019
Idiopathic pulmonary fibrosis
Phase 2
Phase 2 ongoing. Two-thirds of patients enrolled as of February 2016. Enrollment to be completed 3Q 2016. Data due mid 2017
PSDV
$4.00
-0.02  (-0.5%)
Medidur
Posterior uveitis
NDA Filing
Phase 3 data released December 2015. NDA planned for mid 2017
RDHL
$15.40
+0.04  (+0.26%)
BEKINDA
IBS-D
Phase 2
Phase 2 top-line data due mid 2017
ALNY
$75.79
-0.39  (-0.51%)
ALN-HBV
Chronic hepatitis B virus (HBV)
Phase 1/2
Phase 1/2 trial initiated July 2016. Data are due mid 2017
CORT
$5.64
-0.01  (-0.18%)
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 1/2
Phase 1/2 data due 3Q 2017
FLML
$14.89
+0.41  (+2.83%)
Micropump Sodium Oxybate
Narcolepsy
Phase 3
Phase 3 completion due in 3Q 2016
NEOT
$0.84
+0  (+0.01%)
LIPO-202
Reduction of central abdominal bulging
Phase 3
Phase 2 to be initiated 1Q 2017 with data due 3Q 2017
PRTK
$13.32
+0.21  (+1.6%)
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Phase 3
Phase 3 initiated November 2015. Data are due 3Q 2017
VSAR
$13.18
+0.09  (+0.69%)
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
Phase 3
Phase 3 top-line data due 3Q 2017
MESO
$5.57
-0.05  (-0.89%)
MPC-150-IM
Chronic heart failure (CHF)
Phase 3
Phase 3 data due 2H 2017
AIMT
$15.15
+0.22  (+1.47%)
AR101
Peanut Allergy
Phase 3
Phase 3 initiated January 2016. Enrollment to be completed 2H 2016 with trial to be completed 2H 2017
ALDX
$5.59
+0.05  (+1.08%)
NS2
Allergic conjunctivitis
Phase 2
Phase 2/3 trial to begin 2H 2016. Data due 2H 2017
AMAG
$26.33
-0.04  (-0.15%)
Feraheme
Adults with iron deficiency anemia (IDA)
Phase 3
Phase 3 dosing commenced March 2016. sNDA in late 2017.
AVIR
$1.42
+0.02  (+1.43%)
BTA074 5% topical gel
Condyloma
Phase 2
Phase 2 top-line data due 2H 2017
AXON
$16.50
+0.25  (+1.54%)
Intepirdine - MINDSET
Alzheimer’s disease
Phase 3
Phase 3 initiated October 2015. Data are due 2017
AXSM
$7.51
-0.08  (-0.92%)
AXS-02
Complex regional pain syndrome (CRPS)
Phase 3
Initiated July 2015. Expect to complete trial by end of 2017
CLSD
$7.45
+0.37  (+5.23%)
CLS-1001
Macular edema associated with non-infectious uveitis
Phase 3
Phase 3 data due 2H 2017
CPRX
$1.02
-0.06  (-5.56%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3
Phase 3 data due 2H 2017
CRIS
$1.79
+0.05  (+2.87%)
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)
Phase 2
Phase 2 data due 2017
CUR
$0.27
-0.01  (-1.05%)
NSI-189
Major depressive disorder
Phase 2
Phase 2 initiated March 2016. Data are due 2H 2017
CYTK
$12.13
-0.04  (-0.33%)
Tirasemtiv
ALS
Phase 3
Phase 3 enrollment completed August 2016. Data are due 2H 2017
CYTK
$12.13
-0.04  (-0.33%)
CK-2127107
Chronic obstructive pulmonary disease (COPD)
Phase 2
Phase 2 initiated June 2016. Data due 2017
DBVT
$34.96
+0.4  (+1.15%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 1/2
Phase 1/2 data due 2H 2017
DBVT
$34.96
+0.4  (+1.15%)
Viaskin Peanut
Peanut allergy
Phase 3
Phase 3 data due 2H 2017
DERM
$33.89
+0.86  (+2.6%)
DRM04
Primary axillary hyperhidrosis
NDA Filing
Phase 3 data released June 2016. NDA Filing 2H 2017
EARS
$2.03
+0.01  (+0.5%)
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3
Phase 3 HEALOS data due 2H 2017
EIGR
$16.75
+0.05  (+0.3%)
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2
Phase 2 initiated July 2016. Data due 2017
ESPR
$11.29
+0.11  (+0.98%)
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3
Phase 3 long-term safety and tolerability trial initiated January 2015. Top-line results due 4Q 2017
EXEL
$11.61
+0.17  (+1.49%)
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Phase 3
Phase 3 initiated Sept 2013. Data due 2017
FBIO
$2.82
-0.02  (-0.7%)
IV Tramadol
Post-operative Pain
Phase 3
Phase 3 to be initiated 4Q 2016 or 1Q 2017. Data due 4Q 2017
GALT
$1.99
+0.05  (+2.58%)
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 2
Phase 2 top-line data due December 2017
GBT
$19.38
-0.1  (-0.51%)
GBT440
Sickle cell disease
Phase 1/2
Phase 2a initiated June 2016. Data due 2017
GNVC
$0.65
-0.05  (-5.95%)
CGF166
Hearing loss
Phase 1/2
Trial halted January 2016 due to safety review. Clinical hold released July 2016 with trial completion due in 2017.
GWPH
$85.04
+0.66  (+0.78%)
Epidiolex
Tuberous Sclerosis Complex
Phase 3
Phase 3 data due 2H 2017
IRWD
$13.97
+0.17  (+1.23%)
IW-3718
Gastroesophageal reflux disease (GERD)
Phase 2b
Phase 2b initiated March 2016. Data are due in 2017
ITEK
$6.99
-0.01  (-0.15%)
Trabodenoson and latanoprost
Glaucoma
Phase 2
Phase 2 initiated July 2016. Data due 2H 2017
KITE
$60.33
-0.9  (-1.47%)
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Data due 2017
KITE
$60.33
-0.9  (-1.47%)
KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 pivotal trial data due 2017
KITE
$60.33
-0.9  (-1.47%)
KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 1/2
Phase 2 data due 2017
MACK
$5.27
+0.13  (+2.52%)
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Phase 2
Phase 2 initiated August 2014. Data due 2017
MACK
$5.27
+0.13  (+2.52%)
ONIVYDE
Cancer - front line pancreatic
Phase 2
Phase 2 initiated October 2015. Data due 2017
MCRB
$11.55
+0.15  (+1.32%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1/2
Phase 1b initiated July 2016. Data due 2017
MCRB
$11.55
+0.15  (+1.32%)
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b
Phase 1b initiated December 2015. Enrolment ongoing as of May 2016. Data due 2017
MRUS
$9.12
-0.08  (-0.87%)
MCLA-128
Solid tumors
Phase 1/2
Phase 1/2 top-line data due 2H 2017
NBIX
$51.50
-0.03  (-0.05%)
Elagolix
Uterine Fibroids
Phase 3
Phase 3 initiated by partner Abbvie in January 2016. Data due in 2017
NBIX
$51.50
-0.03  (-0.05%)
Elagolix
Endometriosis
NDA Filing
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing due 2017
NBRV
$7.58
+0.08  (+1.07%)
Lefamulin
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3
Phase 3 topline data from two trials due 2H 2017
NEOT
$0.84
+0  (+0.01%)
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2
Phase 3 endpoints not met December 2015. Phase 2 trial to be initiated 4Q 2016 with data due in 2Q 2017
NVLS
$6.03
-0.06  (-0.99%)
N91115
Cystic Fibrosis
Phase 2
Phase 2 enrolment completed July 2016. Data due 4Q 2016
OTIC
$17.26
-0.05  (-0.29%)
OTO-104 AVERTS-1 and AVERTS-2
Ménière’s disease
Phase 3
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017
PBYI
$56.62
+1.97  (+3.6%)
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2
Phase 2 additional data due 4Q 2016
PSTI
$1.68
+0.01  (+0.6%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrolment completed May 2016. Data are due 2017
RARE
$69.36
+1.26  (+1.85%)
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3
Phase 3 data due 2017
RETA
$17.86
+0.28  (+1.59%)
Bardoxolone methyl
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 2
Phase 2 data due 2H 2017
RETA
$17.86
+0.28  (+1.59%)
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 1/2
Phase 1/2 data due 2H 2017
RTRX
$16.98
-0.1  (-0.59%)
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
NDA Filing
NDA filing due 2017
TBPH
$27.98
+0.93  (+3.44%)
Velusetrag (TD-5108)
Gastroparesis
Phase 2
Phase 2 initiated mid March 2015. Data due 2017
TBRA
$4.85
-0.03  (-0.61%)
Cenicriviroc (CVC) - PERSEUS study
Primary sclerosing cholangitis (PSC)
Phase 2a
Phase 2a data due 2017
TCON
$6.60
+0.01  (+0.15%)
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2
Phase 2 dosing initiated May 2016 with data due 2017
TCON
$6.60
+0.01  (+0.15%)
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2
Phase 2 planned for 2015. Data due 2017
TCON
$6.60
+0.01  (+0.15%)
TRC102 and Temodar
Glioblastoma - cancer
Phase 2
Phase 2 trial initiated January 2016. Data due 2017
TCON
$6.60
+0.01  (+0.15%)
TRC102
Mesothelioma cancer
Phase 2
Phase 2 initiated October 2015. Data are due in 2017
TSRO
$92.76
-6.33  (-6.39%)
Niraparib - BRAVO
Cancer - breast
Phase 3
Phase 3 data due 2H 2017
TTPH
$4.11
+0.11  (+2.75%)
Eravacycline (TP-434)
cIAI (complicated intra-abdominal infections)
Phase 3
Announced Dec 17, 2014 that their Phase 3 trial met endpoints. Additional Phase 3 trial required, to be initiated possibly in 4Q 2016 with data 4Q 2017
VBLT
$4.10
+0  (+0%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3
Phase 3 initiated mid 2015. Interim data due 1H 2017. Full data late in 2017 or early 2018
VICL
$4.10
-0.06  (-1.44%)
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3
Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 4Q 2017
VNDA
$12.25
-0.24  (-1.92%)
Tradipitant
Gastroparesis
Phase 2
Phase 2 enrolment to commence 4Q 2016 with data due 2H 2017
VRTX
$100.99
+0.03  (+0.03%)
VX-661
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 3
Phase 3 data due 2H 2017
ALNY
$75.79
-0.39  (-0.51%)
Revusiran ENDEAVOUR
ATTR in patients with familial amyloidotic cardiomyopathy (FAC)
Phase 3
Phase 3 data due early 2018
AVEO
$1.00
-0.02  (-1%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3
Phase 3 dosing commenced May 2016. Data due 1Q 2018
GLMD
$3.95
+0.06  (+1.59%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b
Initiated Phase 2b March 2015. Interim safety analysis due December 2016 or early 2017. Final data due 1Q 2018
OMED
$10.73
+0.25  (+2.39%)
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data are due in late 2017 or in 2018
PRTA
$54.19
-0.15  (-0.29%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b
Phase 2b data due late 2017 or early 2018
VTVT
$5.66
-0.04  (-0.7%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3
Phase 2 data released August 2016. Primary endpoint met.
ALDX
$5.59
+0.05  (+1.08%)
NS2
Noninfectious anterior uveitis
Phase 2
Phase 2/3 to begin 2H 2016. Data expected mid-2018
CFRX
$2.25
-0.04  (-1.75%)
CF-301
Serious infections caused byStaph aureus including MRSA
Phase 2
Phase 2 to be initiated 4Q 2016 with data due 2Q 2018
EARS
$2.03
+0.01  (+0.5%)
AM-111 ASSENT
Acute inner ear hearing loss
Phase 3
Phase 3 ASSENT data due 1H 2018
RETA
$17.86
+0.28  (+1.59%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3
Phase 3 to commence enrolment 2H 2016 with data due 1H 2018
SGEN
$47.79
+0.73  (+1.55%)
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 3
Phase 3 data due between 2017 and mid-2018
SGEN
$47.79
+0.73  (+1.55%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3
Phase 3 enrolment to be completed in 2016. Data are due 2017 or 2018
SNGX
$0.59
+0  (+0.85%)
SGX201
Phase 2b
Phase 2b
Phase 2b data 1H 2018 - pending funding
VTL
$5.97
-0.03  (-0.5%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018
CNCE
$10.94
+0.13  (+1.2%)
AVP-786
Agitation in patients with Alzheimer’s disease
Phase 3
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
ALKS
$46.50
+1.14  (+2.54%)
ALKS 8700
Multiple sclerosis (MS)
Phase 3
Phase 3 trial to be initiated mid-2016 with data due 2018
CPRX
$1.02
-0.06  (-5.56%)
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)
Phase 3
Refusal to file letter reported on Feb 17 2016 for Dec 2015 NDA Filing. Additional Phase 3 trial planned for 4Q 2016. Data due 2H 2017
FGEN
$19.11
+0.06  (+0.31%)
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 3
Phase 3 ongoing. Expects to file NDA in 2018 assuming positive data
INCY
$81.90
-0.08  (-0.1%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018
MACK
$5.27
+0.13  (+2.52%)
MM-141
Cancer - front line pancreatic cancer
Phase 2
Phase 2 data due 2018
MACK
$5.27
+0.13  (+2.52%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2
Phase 2 initiated mid Feb 2015. Data due 2018
MGNX
$31.43
-0.37  (-1.16%)
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 3
Phase 3 enrolling. Completion of trial expected in 2018
SNGX
$0.59
+0  (+0.85%)
SGX203
Pediatric Crohn’s Disease
Phase 3
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding
TBPH
$27.98
+0.93  (+3.44%)
Telavancin
Bacteremia
Phase 3
Phase 3 data due 2018
XNCR
$21.67
-0.09  (-0.41%)
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2
Phase 2 trial initiated March 2016. Initial data due 2018
AKBA
$8.42
+0.2  (+2.43%)
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
Phase 3
Phase 3 initiated January 2016. NDA to be filed 2019 assuming postive data
ESPR
$11.29
+0.11  (+0.98%)
Bempedoic acid
Hypercholesterolemia - statin intolerance
Phase 2
Phase 3 efficacy study to be initiated 4Q 2016. NDA to be filed by 2022